[go: up one dir, main page]

MX2009001631A - Formulacion farmaceutica para el tratamiento de afecciones en la piel. - Google Patents

Formulacion farmaceutica para el tratamiento de afecciones en la piel.

Info

Publication number
MX2009001631A
MX2009001631A MX2009001631A MX2009001631A MX2009001631A MX 2009001631 A MX2009001631 A MX 2009001631A MX 2009001631 A MX2009001631 A MX 2009001631A MX 2009001631 A MX2009001631 A MX 2009001631A MX 2009001631 A MX2009001631 A MX 2009001631A
Authority
MX
Mexico
Prior art keywords
treatment
pharmaceutical formulation
complaints
relates
mainly
Prior art date
Application number
MX2009001631A
Other languages
English (en)
Inventor
Barranco Enrique Rossell
Original Assignee
Klever Mode S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klever Mode S L filed Critical Klever Mode S L
Publication of MX2009001631A publication Critical patent/MX2009001631A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una formulación farmacéutica caracterizada porque comprende principalmente clobetasolpropionato, minoxidil, y 11 alfa hidroxiprogesterona como principios activos además de otros excipientes, vitaminas y/o minerales, y a su uso en el tratamiento de afecciones en la piel, principalmente en el tratamiento sintomático de psoriasis.
MX2009001631A 2006-08-17 2006-08-22 Formulacion farmaceutica para el tratamiento de afecciones en la piel. MX2009001631A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06380229A EP1891960B1 (en) 2006-08-17 2006-08-17 Pharmaceutical formula for treating skin disease
PCT/ES2006/000483 WO2008020091A1 (es) 2006-08-17 2006-08-22 Formulación farmacéutica para el tratamiento de afecciones

Publications (1)

Publication Number Publication Date
MX2009001631A true MX2009001631A (es) 2009-06-19

Family

ID=37499927

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001631A MX2009001631A (es) 2006-08-17 2006-08-22 Formulacion farmaceutica para el tratamiento de afecciones en la piel.

Country Status (15)

Country Link
US (1) US7671044B2 (es)
EP (1) EP1891960B1 (es)
CN (1) CN101522198B (es)
AT (1) ATE444071T1 (es)
AU (1) AU2006347403A1 (es)
BR (1) BRPI0621966A2 (es)
CA (1) CA2661064A1 (es)
DE (1) DE602006009511D1 (es)
DK (1) DK1891960T3 (es)
ES (1) ES2334381T3 (es)
IL (1) IL197035A0 (es)
MX (1) MX2009001631A (es)
PT (1) PT1891960E (es)
RU (1) RU2432952C2 (es)
WO (1) WO2008020091A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2893979B2 (es) * 2020-08-01 2023-02-21 Mc Zosimo S L Procedimiento para la obtención de una formulación para el tratamiento de dermatitis inflamatorias y producto obtenido

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903344B1 (en) * 1997-08-21 2011-01-26 Shiseido Co., Ltd. Quinazolin-4-one derivatives, their preparation and their use as hair growth promoters or in external compositions for skin
AU3212099A (en) * 1998-03-31 1999-10-18 Johnson & Johnson Consumer Companies, Inc. Method for increasing the permeability of horny human tissue
SI3146969T1 (en) * 1999-04-23 2018-08-31 Leo Pharma A/S Ointment for topical treatment of psoriasis
ES2188426B1 (es) * 2001-12-12 2004-11-16 Rosalia Pidal Fernandez Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.
ATE410184T1 (de) * 2003-02-05 2008-10-15 Galderma Res & Dev Umkehremulsion mit mindestens einem gegenüber wasser empfindlichen wirkstoff und ihre anwendungen in kosmetik und dermatologie
WO2006051287A1 (en) * 2004-11-10 2006-05-18 Arrow International Limited Composition and method for treatment of alopecia areata

Also Published As

Publication number Publication date
EP1891960B1 (en) 2009-09-30
EP1891960A1 (en) 2008-02-27
BRPI0621966A2 (pt) 2011-12-27
RU2009109356A (ru) 2010-09-27
DE602006009511D1 (de) 2009-11-12
WO2008020091A8 (es) 2009-04-02
US20080045487A1 (en) 2008-02-21
ATE444071T1 (de) 2009-10-15
AU2006347403A1 (en) 2008-02-21
ES2334381T3 (es) 2010-03-09
CA2661064A1 (en) 2008-02-21
IL197035A0 (en) 2009-11-18
CN101522198B (zh) 2011-10-05
CN101522198A (zh) 2009-09-02
US7671044B2 (en) 2010-03-02
WO2008020091A1 (es) 2008-02-21
RU2432952C2 (ru) 2011-11-10
PT1891960E (pt) 2010-01-04
DK1891960T3 (da) 2010-02-01

Similar Documents

Publication Publication Date Title
MY178634A (en) Topical formulation for a jak inhibitor
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
LUC00011I2 (es)
MY143795A (en) Tetrahydropyridoindole derivatives
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
TW200637522A (en) Skin treatment articles and methods
NZ605469A (en) Nalbuphine-based formulations and uses thereof
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
SA519410993B1 (ar) النشاط المضاد للبكتيريا لأوليجو سكاريد من جالاكتو وزيليتول في العلاجات الجلدية
MX347237B (es) Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
PT1893237E (pt) Composição farmacêutica compreendendo um elastómero organopolissiloxano e um princípio activo solubilizado
MX2009001631A (es) Formulacion farmaceutica para el tratamiento de afecciones en la piel.
PL1874410T3 (pl) Odbarwiająca lub rozjaśniająca kompozycja kosmetyczna zawierająca co najmniej jedną oksazolinę jako składnik aktywny
PL1781292T3 (pl) Formulacja o przedłużonym uwalnianiu 3-amino-8-(1-piperazynylo)-2H-1-benzopiran-2-onu
TW200700084A (en) Combination of sodium channel blockers and their derivatives with opioid antagonists
SI1817029T1 (sl) Derivati izoksazola za lajĺ anje nevropatskih boleäśin

Legal Events

Date Code Title Description
FG Grant or registration